HOTH - Spark Newswire

3 minute read

The Daily Biotech Pulse: AstraZeneca’s COVID-19 Vaccine As Effective As mRNA Shots, Humanigen’s Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth’s Alzheimer’s Program

By Vandana Singh

Today, 1:53 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AGIO

1 minute read

Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer’s Program

By Vandana Singh

Today, 1:53 PM

Hoth Therapeutics Inc (NASDAQ:HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer’s disease mouse model. HT-ALZ…

HOTH

1 minute read

Why Hoth Therapeutics Shares Are Skyrocketing Today

By Henry Khederian

Today, 1:53 PM

Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher by 17% to $0.47 Tuesday morning after the company announced its HT-ALZ therapeutic showed cognitive improvements in an Alzheimer's Disease (AD) mouse model.

HOTH

3 minute read

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements In Alzheimer’s Disease Mouse Model; Shares Halted On Circuit Breaker

By Benzinga Newsdesk

Today, 1:53 PM

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease

HOTH

3 minute read

Recap of Tuesday’s Biotech Catalysts – End of the Day Summary

By Ragothaman Srinivasan

Today, 1:53 PM

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

ABBV

1 minute read

FDA
News

Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis

By Benzinga Newsdesk

Today, 1:53 PM

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC)

HOTH

1 minute read

Hoth Therapeutics Announces Extension Of Washington University Alzheimer’s Mouse Model Study With Alzheimer’s Therapeutic HT-ALZ

By Bill Haddad

Today, 1:53 PM

The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials NEW YORK, June 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a

HOTH

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 1:53 PM

On Wednesday, 807 companies reached new 52-week lows.

AADI

1 minute read

Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury

By Vandana Singh

Today, 1:53 PM

Hoth Therapeutics Inc (NASDAQ:HOTH) has added a new asset, HT-TBI, as a novel, point-of-care therapy to treat secondary brain injury…

HOTH

1 minute read

Why Fulgent Genetics Shares Are Trading Higher Today

By Vandana Singh

Today, 1:53 PM

Fulgent Genetics Inc (NASDAQ:HOTH) agreed to acquire Inform Diagnostics, an independent pathology laboratory based in Irving, Texas, and a portfolio company…

FLGT

Feed Symbols: HOTH